Time-dependent changes in neurokinin(3) receptors and tachykinins during adjuvant-induced peripheral inflammation in the rat.

Neuroscience

Department of Neuroscience, University of Minnesota, 6-145 Jackson Hall, 321 Church Street S.E., Minneapolis, MN 55455, USA.

Published: September 2000

Although considerable evidence exists that spinal neurokinin(1) receptors are involved in central sensitization of nociception, recent evidence from knockout studies indicates that other neurokinin receptors in the spinal cord may mediate a portion of the hyperalgesia caused by substance P and neurokinin A. The present study determined whether the second most abundant class of neurokinin receptors, neurokinin(3) receptors, are regulated during persistent peripheral inflammation. Inflammation in the hind paw of the rat was induced by intraplantar injection of complete Freund's adjuvant. Receptor autoradiography revealed specific binding of [125I]-MePhe(7)-NKB, a selective ligand for neurokinin(3) receptors, in the superficial dorsal horn of the spinal cord. Specific binding of [125I]-MePhe(7)-NKB in the medial dorsal horn was reduced bilaterally two days after unilateral injection of complete Freund's adjuvant. Binding returned to basal levels four days after injection of complete Freund's adjuvant. Neurokinin(3) receptor messenger RNA levels doubled in the dorsal spinal cord at 12h and remained elevated for at least four days. The change in neurokinin(3) receptor binding and messenger RNA during adjuvant-induced inflammation may be a consequence of activation of the receptor. Spinal levels of potential endogenous ligands for spinal neurokinin(3) receptors were measured by radioimmunohistochemistry. Immunoreactive substance P but not neurokinin B peptide 2, a marker for neurokinin B, was reduced bilaterally during adjuvant-induced inflammation.Collectively, these data indicate that spinal neurokinin(3) receptors may play a role in spinal neurotransmission of injured rats and require consideration of other tachykinins as physiologically relevant ligands to spinal neurokinin(3) receptors.

Download full-text PDF

Source
http://dx.doi.org/10.1016/s0306-4522(00)00160-3DOI Listing

Publication Analysis

Top Keywords

neurokinin3 receptors
24
spinal cord
12
injection complete
12
complete freund's
12
freund's adjuvant
12
spinal neurokinin3
12
receptors
9
spinal
9
neurokinin3
8
peripheral inflammation
8

Similar Publications

Menopause is an increasingly discussed topic in recent years. More women are demanding consultancy and help from their doctors via different channels, be it online or in menopause centers.The term genitourinary syndrome of menopause (GSM) comprises vaginal and urological symptoms such as mucosal dryness, itching and burning, dysuria or bleeding and pain during sexual intercourse.

View Article and Find Full Text PDF
Article Synopsis
  • Vasomotor symptoms (VMS), such as hot flashes and night sweats, commonly disrupt the quality of life during menopause, and fezolinetant is a non-hormonal treatment approved by the FDA to address these symptoms.
  • The study involved analyzing six randomized controlled trials with a total of 3,301 postmenopausal women, demonstrating that fezolinetant significantly reduced both the frequency and severity of VMS episodes compared to a placebo at four and twelve weeks.
  • Although fezolinetant showed positive results in alleviating VMS, it also presented increased risks for certain adverse effects, including fatigue and elevated liver enzyme levels, indicating a need for careful consideration of its safety
View Article and Find Full Text PDF
Article Synopsis
  • Vasomotor symptoms (VMS) significantly affect the quality of life and sleep for many postmenopausal individuals.
  • This systematic review assesses the safety and effectiveness of neurokinin-3 receptor antagonists like fezolinetant and elinzanetant for alleviating VMS in these patients.
  • The analysis of six randomized controlled trials found that fezolinetant effectively reduced VMS frequency and severity and improved quality of life and sleep, with no serious adverse effects reported; similar positive outcomes were seen with elinzanetant.
View Article and Find Full Text PDF

Sporadic or late-onset Alzheimer's disease (LOAD) accounts for more than 95% of Alzheimer's disease (AD) cases without any family history. Although genome-wide association studies have identified associated risk genes and loci for LOAD, numerous studies suggest that many adverse environmental factors, such as social isolation, are associated with an increased risk of dementia. However, the underlying mechanisms of social isolation in AD progression remain elusive.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!